Historical Valuation
Merck & Co Inc (MRK) is now in the Fair zone, suggesting that its current forward PE ratio of 12.32 is considered Fairly compared with the five-year average of 16.86. The fair price of Merck & Co Inc (MRK) is between 61.18 to 269.67 according to relative valuation methord.
Relative Value
Fair Zone
61.18-269.67
Current Price：108.26
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Merck & Co Inc (MRK) has a current Price-to-Book (P/B) ratio of 5.11. Compared to its 3-year average P/B ratio of 6.07 , the current P/B ratio is approximately -15.88% higher. Relative to its 5-year average P/B ratio of 6.03, the current P/B ratio is about -15.27% higher. Merck & Co Inc (MRK) has a Forward Free Cash Flow (FCF) yield of approximately 4.94%. Compared to its 3-year average FCF yield of 4.96%, the current FCF yield is approximately -0.34% lower. Relative to its 5-year average FCF yield of 4.85% , the current FCF yield is about 1.87% lower.
Competitors Valuation Multiple
AI Analysis
The average P/S ratio for MRK competitors is 4.60, providing a benchmark for relative valuation. Merck & Co Inc Corp (MRK.N) exhibits a P/S ratio of 3.95, which is -13.97% above the industry average. Given its robust revenue growth of 3.72%, this premium appears unsustainable.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of MRK increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MRK in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MRK currently overvalued or undervalued?
Merck & Co Inc (MRK) is now in the Fair zone, suggesting that its current forward PE ratio of 12.32 is considered Fairly compared with the five-year average of 16.86. The fair price of Merck & Co Inc (MRK) is between 61.18 to 269.67 according to relative valuation methord.
What is Merck & Co Inc (MRK) fair value?
MRK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Merck & Co Inc (MRK) is between 61.18 to 269.67 according to relative valuation methord.
How does MRK's valuation metrics compare to the industry average?
The average P/S ratio for MRK's competitors is 4.60, providing a benchmark for relative valuation. Merck & Co Inc Corp (MRK) exhibits a P/S ratio of 3.95, which is -13.97% above the industry average. Given its robust revenue growth of 3.72%, this premium appears unsustainable.
What is the current P/B ratio for Merck & Co Inc (MRK) as of Jan 14 2026?
As of Jan 14 2026, Merck & Co Inc (MRK) has a P/B ratio of 5.11. This indicates that the market values MRK at 5.11 times its book value.
What is the current FCF Yield for Merck & Co Inc (MRK) as of Jan 14 2026?
As of Jan 14 2026, Merck & Co Inc (MRK) has a FCF Yield of 4.94%. This means that for every dollar of Merck & Co Inc’s market capitalization, the company generates 4.94 cents in free cash flow.
What is the current Forward P/E ratio for Merck & Co Inc (MRK) as of Jan 14 2026?
As of Jan 14 2026, Merck & Co Inc (MRK) has a Forward P/E ratio of 12.32. This means the market is willing to pay $12.32 for every dollar of Merck & Co Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Merck & Co Inc (MRK) as of Jan 14 2026?
As of Jan 14 2026, Merck & Co Inc (MRK) has a Forward P/S ratio of 3.95. This means the market is valuing MRK at $3.95 for every dollar of expected revenue over the next 12 months.